This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Siponimod for secondary progressive multiple sclerosis

< Back

Siponimod for secondary progressive multiple sclerosis


Neurology and Neurosurgery

September 2016

Siponimod is a new drug that is taken by mouth to treat patients with secondary progressive multiple sclerosis (MS). MS is a condition which can affect the brain and/or spinal cord. It causes a wide range of symptoms, including problems with memory, sight, speech and swallowing, arm or leg sensation and movement, bladder and bowel function, and balance. Some studies have suggested that siponimod may be able to reduce symptoms in patients with MS by decreasing cells that cause inflammation.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts